| Revision as of 11:46, 14 December 2010 editKupirijo (talk | contribs)Extended confirmed users9,131 edits Category:Phosphonic acids Category:Amino acids← Previous edit |
Latest revision as of 16:28, 17 September 2023 edit undoKoIobok (talk | contribs)Extended confirmed users1,350 edits Changed Category:Amino acids to Category:Alpha-Amino acids |
| (22 intermediate revisions by 17 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{drugbox | |
|
|
|
{{Drugbox |
| ⚫ |
| IUPAC_name = (E,2R)-2-amino-4-methyl-5-phosphonopent-3-enoic acid |
|
|
|
| Verifiedfields = changed |
| ⚫ |
| image = CGP-37849.png |
|
|
|
| Watchedfields = changed |
| ⚫ |
| width = 240 |
|
|
|
| verifiedrevid = 402321381 |
| ⚫ |
| CAS_number = 137424-81-8 |
|
|
⚫ |
| IUPAC_name = (E,2R)-2-amino-4-methyl-5-phosphonopent-3-enoic acid |
| ⚫ |
| synonyms = CGP-37849, CGP-40116 |
|
|
⚫ |
| image = CGP-37849.svg |
| ⚫ |
| ATC_prefix = |
|
|
⚫ |
| width = 240 |
| ⚫ |
| ATC_suffix = |
|
|
| PubChem = 5950212 |
|
| ⚫ |
| DrugBank = |
|
| ⚫ |
| C = 6 | H = 12 | N = 1 | O = 5 | P = 1 |
|
|
| molecular_weight = 209.137 g/mol |
|
| ⚫ |
| smiles = C/C(=C\(C(=O)O)N)/CP(=O)(O)O |
|
| ⚫ |
| bioavailability = |
|
| ⚫ |
| protein_bound = |
|
| ⚫ |
| metabolism = |
|
| ⚫ |
| elimination_half-life = |
|
| ⚫ |
| excretion = |
|
| ⚫ |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| ⚫ |
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| ⚫ |
| pregnancy_category= |
|
| ⚫ |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
| ⚫ |
| legal_CA = |
|
| ⚫ |
| legal_UK = |
|
| ⚫ |
| legal_US = |
|
| ⚫ |
| legal_status = |
|
| ⚫ |
| routes_of_administration = |
|
| ⚫ |
}} |
|
|
|
|
|
|
|
<!--Clinical data--> |
| ⚫ |
'''CGP-37849''' is a competitive ] at the ].<ref>Fagg GE, Olpe HR, Pozza MF, Baud J, Steinmann M, Schmutz M, Portet C, Baumann P, Thedinga K, Bittiger H, et al. CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity. ''British Journal of Pharmacology''. 1990 Apr;99(4):791-7. PMID 1972895</ref> It is a potent, orally active ] in animal models,<ref>Schmutz M, Portet C, Jeker A, Klebs K, Vassout A, Allgeier H, Heckendorn R, Fagg GE, Olpe HR, van Riezen H. The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents. ''Naunyn-Schmiedebergs Archives of Pharmacology''. 1990 Jul;342(1):61-6. PMID 1976233</ref> and was researched for the treatment of ].<ref>Fujikawa DG, Daniels AH, Kim JS. The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage. ''Epilepsy Research''. 1994 Mar;17(3):207-19. PMID 7912191</ref> It also has ] activity<ref>Gutnikov SA, Gaffan D. Systemic NMDA receptor antagonist CGP-40116 does not impair memory acquisition but protects against NMDA neurotoxicity in rhesus monkeys. ''Journal of Neuroscience''. 1996 Jun 15;16(12):4041-5. PMID 8656297</ref> and shows ]<ref>Maj J, Klimek V, Gołembiowska K, Rogóz Z, Skuza G. Central effects of repeated treatment with CGP 37849, a competitive NMDA receptor antagonist with potential antidepressant activity. ''Polish Journal of Pharmacology''. 1993 Sep-Dec;45(5-6):455-66. PMID 7912134</ref><ref>Papp M, Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. ''European Journal of Pharmacology''. 1994 Sep 22;263(1-2):1-7. PMID 7821340</ref> and ] effects.<ref>Jessa M, Nazar M, Bidzinski A, Plaznik A. The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety. ''European Neuropsychopharmacology''. 1996 Mar;6(1):55-61. PMID 8866939</ref><ref>Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E. The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. ''Neuropharmacology''. 2000 Jul 24;39(10):1858-64. PMID 10884566</ref> |
|
|
|
| tradename = |
|
⚫ |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
⚫ |
| pregnancy_US = <!-- A / B / C / D / X --> |
|
⚫ |
| pregnancy_category = |
|
⚫ |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
⚫ |
| legal_CA = |
|
⚫ |
| legal_UK = |
|
⚫ |
| legal_US = |
|
⚫ |
| legal_status = |
|
⚫ |
| routes_of_administration = |
|
|
|
|
|
|
<!--Pharmacokinetic data--> |
|
⚫ |
| bioavailability = |
|
⚫ |
| protein_bound = |
|
⚫ |
| metabolism = |
|
⚫ |
| elimination_half-life = |
|
⚫ |
| excretion = |
|
|
|
|
|
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|correct|CAS}} |
|
⚫ |
| CAS_number = 137424-81-8 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = 76IND1BS43 |
|
⚫ |
| ATC_prefix = |
|
⚫ |
| ATC_suffix = |
|
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
⚫ |
| DrugBank = |
|
|
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
|
|
| ChEMBL = 29811 |
|
|
| PubChem = 6604869 |
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
|
| ChemSpiderID = 5037128 |
|
|
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} |
|
|
| StdInChI = 1S/C6H12NO5P/c1-4(3-13(10,11)12)2-5(7)6(8)9/h2,5H,3,7H2,1H3,(H,8,9)(H2,10,11,12)/b4-2+/t5-/m1/s1 |
|
|
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} |
|
|
| StdInChIKey = BDYHNCZIGYIOGJ-XWCPEMDWSA-N |
|
|
|
|
|
<!--Chemical data--> |
|
⚫ |
| C=6 | H=12 | N=1 | O=5 | P=1 |
|
⚫ |
| smiles = C/C(=C\(C(=O)O)N)/CP(=O)(O)O |
|
⚫ |
| synonyms = CGP-37849, CGP-40116 |
|
⚫ |
}} |
|
|
|
|
|
⚫ |
'''CGP-37849''' is a competitive ] at the ].<ref>{{cite journal | vauthors = Fagg GE, Olpe HR, Pozza MF, Baud J, Steinmann M, Schmutz M, Portet C, Baumann P, Thedinga K, Bittiger H | display-authors = 6 | title = CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity | journal = British Journal of Pharmacology | volume = 99 | issue = 4 | pages = 791–7 | date = April 1990 | pmid = 1972895 | pmc = 1917531 | doi = 10.1111/j.1476-5381.1990.tb13008.x }}</ref> It is a potent, orally active ] in animal models,<ref>{{cite journal | vauthors = Schmutz M, Portet C, Jeker A, Klebs K, Vassout A, Allgeier H, Heckendorn R, Fagg GE, Olpe HR, van Riezen H | display-authors = 6 | title = The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents | journal = Naunyn-Schmiedeberg's Archives of Pharmacology | volume = 342 | issue = 1 | pages = 61–6 | date = July 1990 | pmid = 1976233 | doi = 10.1007/bf00178973 | s2cid = 25531153 }}</ref> and was researched for the treatment of ].<ref>{{cite journal | vauthors = Fujikawa DG, Daniels AH, Kim JS | title = The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage | journal = Epilepsy Research | volume = 17 | issue = 3 | pages = 207–19 | date = March 1994 | pmid = 7912191 | doi = 10.1016/0920-1211(94)90051-5 | s2cid = 13656613 }}</ref> It also has ] activity<ref>{{cite journal | vauthors = Gutnikov SA, Gaffan D | title = Systemic NMDA receptor antagonist CGP-40116 does not impair memory acquisition but protects against NMDA neurotoxicity in rhesus monkeys | journal = The Journal of Neuroscience | volume = 16 | issue = 12 | pages = 4041–5 | date = June 1996 | pmid = 8656297 | pmc = 6578604 | doi = 10.1523/JNEUROSCI.16-12-04041.1996 }}</ref> and shows ]<ref>{{cite journal | vauthors = Maj J, Klimek V, Gołembiowska K, Rogóz Z, Skuza G | title = Central effects of repeated treatment with CGP 37849, a competitive NMDA receptor antagonist with potential antidepressant activity | journal = Polish Journal of Pharmacology | volume = 45 | issue = 5–6 | pages = 455–66 | pmid = 7912134 | year = 1993 }}</ref><ref>{{cite journal | vauthors = Papp M, Moryl E | title = Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression | journal = European Journal of Pharmacology | volume = 263 | issue = 1–2 | pages = 1–7 | date = September 1994 | pmid = 7821340 | doi = 10.1016/0014-2999(94)90516-9 }}</ref> and ] effects.<ref>{{cite journal | vauthors = Jessa M, Nazar M, Bidzinski A, Plaznik A | title = The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety | journal = European Neuropsychopharmacology | volume = 6 | issue = 1 | pages = 55–61 | date = March 1996 | pmid = 8866939 | doi = 10.1016/0924-977x(95)00068-z | s2cid = 45953054 }}</ref><ref>{{cite journal | vauthors = Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E | title = The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats | journal = Neuropharmacology | volume = 39 | issue = 10 | pages = 1858–64 | date = July 2000 | pmid = 10884566 | doi = 10.1016/s0028-3908(00)00023-x | s2cid = 33660694 }}</ref> |
| ⚫ |
==References== |
|
|
<references/> |
|
|
|
|
|
|
⚫ |
== References == |
|
{{Glutamate_receptor_ligands}} |
|
|
|
{{reflist}} |
|
|
|
|
|
|
{{Ionotropic glutamate receptor modulators}} |
|
|
|
|
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
|
] |